| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/27/2007 | EP1799637A1 Substituted sulfonamidopropionamides and methods of use |
| 06/27/2007 | EP1799636A2 Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives |
| 06/27/2007 | EP1799634A2 Diphenylethylene compounds and uses thereof |
| 06/27/2007 | EP1799633A2 Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
| 06/27/2007 | EP1799306A2 Compositions and methods for treating cognitive disorders |
| 06/27/2007 | EP1799269A2 Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| 06/27/2007 | EP1799266A2 Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| 06/27/2007 | EP1799265A1 Stable dosing form of phenylalanine derivatives |
| 06/27/2007 | EP1799264A2 Methods and compositions for treating migraine pain |
| 06/27/2007 | EP1799243A2 Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| 06/27/2007 | EP1799232A2 Self-gelling alginate systems and uses thereof |
| 06/27/2007 | EP1799231A1 Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases |
| 06/27/2007 | EP1799230A2 Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
| 06/27/2007 | EP1799229A1 Pulmonary administration of an antithrombotic compound |
| 06/27/2007 | EP1799228A1 Topical compositions containing phosphorylated polyphenols |
| 06/27/2007 | EP1799227A2 Therapeutic agents targeting the nc ca-atp channel and methods of use thereof |
| 06/27/2007 | EP1799226A1 Use of midostaurin for treating gastrointestinal stromal tumors |
| 06/27/2007 | EP1799225A1 Use of paullone derivates for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells |
| 06/27/2007 | EP1799224A1 Memantine for the treatment of childhood behavioral disorders |
| 06/27/2007 | EP1799223A2 Arylthiobenzylpiperidine derivates |
| 06/27/2007 | EP1799222A2 Compounds that inhibit replication of human immunodeficiency virus |
| 06/27/2007 | EP1799221A1 Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
| 06/27/2007 | EP1799220A1 Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain |
| 06/27/2007 | EP1799219A1 Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain |
| 06/27/2007 | EP1799218A1 Hcv inhibiting bi-cyclic pyrimidines |
| 06/27/2007 | EP1799217A1 Compounds and methods of treating insulin resistance and cardiomyopathy |
| 06/27/2007 | EP1799216A2 Tadalafil crystal forms and processes for preparing them |
| 06/27/2007 | EP1799215A2 Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| 06/27/2007 | EP1799214A1 Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom |
| 06/27/2007 | EP1799213A2 Novel curcumin analogues and uses thereof |
| 06/27/2007 | EP1799212A2 Compounds for nonsense suppression, and methods for their use |
| 06/27/2007 | EP1799211A1 Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient |
| 06/27/2007 | EP1799210A1 A guanylate cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasconstriction |
| 06/27/2007 | EP1799209A1 Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent |
| 06/27/2007 | EP1799208A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 06/27/2007 | EP1799207A2 Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| 06/27/2007 | EP1799206A2 Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor |
| 06/27/2007 | EP1799205A1 Medicaments for inhalation comprising pde iv inhibitors and enantiomercally pure glycopyrrolate salts |
| 06/27/2007 | EP1799204A1 Composition containing omega-3 fatty acids and omega-6 fatty acids |
| 06/27/2007 | EP1799203A1 Agent for prophylaxis or treatment of metabolic syndrome |
| 06/27/2007 | EP1799202A1 Therapeutical agent useful for the treatment of plasma cell neoplasias |
| 06/27/2007 | EP1799201A1 4-hydroxy tamoxifen gel formulations |
| 06/27/2007 | EP1799200A1 Polyamine analogs as therapeutic agents for ocular diseases |
| 06/27/2007 | EP1799199A1 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
| 06/27/2007 | EP1799198A1 Methods and compositions for the treatment of diseases characterized by pathological calcification |
| 06/27/2007 | EP1799190A1 Oral pharmaceutical preparation for proton pump antagonists |
| 06/27/2007 | EP1799186A1 Octenidine-containing lozenges used against inflammatory oral and pharyngeal diseases |
| 06/27/2007 | EP1799150A2 Covered stent with controlled therapeutic agent diffusion |
| 06/27/2007 | EP1727815B1 Ether derivatives, their manufacture and use as pharmaceutical agents |
| 06/27/2007 | EP1689708B1 N-acyl-n -benzyl-alkylendiamino derivatives |
| 06/27/2007 | EP1684766B1 USE OF 3-AZA-1-OXA-DIBENZO i e,h /i AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEAS AND DISORDERS |
| 06/27/2007 | EP1682532B1 Pyrimidines as inhibitors of phosphoinositide-3-kinases (pi3k) |
| 06/27/2007 | EP1658054B1 Dosage form that is safeguarded from abuse |
| 06/27/2007 | EP1636212B1 Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents |
| 06/27/2007 | EP1620562A4 Modulation of telomere-initiated cell signaling |
| 06/27/2007 | EP1620392B1 Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents |
| 06/27/2007 | EP1590352B1 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS |
| 06/27/2007 | EP1567525B1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 06/27/2007 | EP1551391B1 Dry syrup preparation of procaterol comprising ascorbic acid and citric acid |
| 06/27/2007 | EP1539181B1 Method of treating lower urinary tract disorders |
| 06/27/2007 | EP1531812B1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthritis |
| 06/27/2007 | EP1525177B1 Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
| 06/27/2007 | EP1504004B1 Substituted pyrazolopyrimidines |
| 06/27/2007 | EP1490034B1 Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions |
| 06/27/2007 | EP1485376B1 Compositions useful as inhibitors of protein kinases |
| 06/27/2007 | EP1471874A4 Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| 06/27/2007 | EP1414416A4 Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| 06/27/2007 | EP1401277B1 Amenoacetonitrile compounds for controlling endoparasites |
| 06/27/2007 | EP1392259B1 Delivery of erectile dysfunction drugs through an inhalation route |
| 06/27/2007 | EP1378236B1 Agents against stress-induced diseases |
| 06/27/2007 | EP1368312B1 Benzo[f]isoindole derivatives with affinity to the ep4 receptor |
| 06/27/2007 | EP1366025B1 Agonists of beta-adrenoreceptors |
| 06/27/2007 | EP1343779B1 Novel compounds |
| 06/27/2007 | EP1311264B1 Substituted and non-substituted benzooxathiazoles and compounds derived therefrom |
| 06/27/2007 | EP1301485B1 Novel heteroaryl derivatives and the use thereof as pharmaceuticals |
| 06/27/2007 | EP1289503B1 O/w emulsion |
| 06/27/2007 | EP1284973B1 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 06/27/2007 | EP1280784B1 Biologically active 4h-benzo 1,4|oxazin-3-ones |
| 06/27/2007 | EP1272459B1 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds |
| 06/27/2007 | EP1233755B1 Hydrolyzed cellulose granulations of salts of drugs |
| 06/27/2007 | EP1219630B1 Immunopotentiating compositions |
| 06/27/2007 | EP1212063B1 Topical azathioprine for the treatment of oral autoimmune diseases |
| 06/27/2007 | EP1144366B1 3,4-disubstituted acylanilide derivatives and their use as androgen receptor suppressors |
| 06/27/2007 | EP1140873B1 Il-5 inhibiting 6-azauracil derivatives |
| 06/27/2007 | EP1121436B1 Non-desensitizing ampa-receptors |
| 06/27/2007 | EP1115383B1 Treatment of acute disorders by sublingual administration of a pharmaceutical composition |
| 06/27/2007 | EP1061913B1 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy |
| 06/27/2007 | EP1047676B1 Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation |
| 06/27/2007 | EP0981549B2 Use of an inhibitor substance for the improvement of neuronal regeneration |
| 06/27/2007 | EP0954340B1 Targeted combination immunotherapy of cancer |
| 06/27/2007 | EP0863903B1 Synthetic metal-substituted bacteriochlorophyll derivatives and use thereof |
| 06/27/2007 | CN1989439A Methods and compositions for the treatment of uveitis |
| 06/27/2007 | CN1989254A Processes for producing cellooligosaccharide |
| 06/27/2007 | CN1989244A Inhibitors of tgf-r signaling for treatment of cns disorders |
| 06/27/2007 | CN1989146A Sulfated oligosaccharide derivatives |
| 06/27/2007 | CN1989144A N-phenylphosphoric acid triamides, method for the production thereof and their use as agents for regulating or inhibiting enzymatic urea hydrolysis |
| 06/27/2007 | CN1989141A Bicyclic heterocycles as HIV integrase inhibitors |
| 06/27/2007 | CN1989140A Compounds containing a n-heteroaryl moiety linked to fused ring moieties for the inhibition of nad(p)h oxidases and platelet activation |
| 06/27/2007 | CN1989139A Benzothiazole derivatives |
| 06/27/2007 | CN1989138A 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders |